Ebovir, a Canadian biotech company, is on a mission to support biopharma companies with basic viral research and the development of novel biopharma therapies against deadly viruses.
From the initial stages of discovery through structure-activity relationship evaluation, lead identification, and preclinical development directed toward investigational new drug application (INDA) submission, Ebovir assists clients in each step.
The company has diversified its objectives into short-term and long-term goals. In the short-term, Ebovir functions as a contract research organization (CRO) with a comprehensive suite of offerings. This includes antiviral drug screening, clinical trials, and validation services for vaccine and drug development companies looking to assess small molecules, natural products, immune modulators, biologics, and therapeutic antibodies.
As part of its long-term goals, the company channelizes all profits generated from the CRO services to fuel its proprietary antiviral therapy development, especially for respiratory syncytial virus (RSV), for which no drugs are currently available.
Incorporating artificial intelligence (AI) into the design and study of these drugs allows for the identification and targeting of conserved viral enzymes or proteins across pandemic respiratory viruses. Leveraging AI streamlines the process of discovering and optimizing broad-spectrum antiviral agents. This integration significantly enhances Ebovir’s ability to expedite the progression of its antiviral drug pipeline by efficiently reevaluating and furthering the development of promising therapeutic candidates.
“Our strategic approach to CRO services allows us to support our valued clients with all aspects of viral basic research and drives our pursuit of developing breakthrough antiviral therapies,” says Zhenlong Liu, PhD, Co-founder.
Ebovir’s scientific prowess and operational efficiency enables clients to easily address these challenges. The company’s scientist board members are professors from famous Canadian universities with vast experience in virology and viral immunology. Their understanding of industry developments and regulatory frameworks helps clients stay compliant with new and evolving mandates.
Biopharma companies have to encounter the inherently resilient nature of viruses as they continually produce new variants through mutations. Their adaptability makes them adept at evading therapeutic interventions and even our immune system. This makes it challenging to develop effective therapies that can keep pace with the virus's ability to mutate.
Our strategic approach to CRO services allows us to support our valued clients with all aspects of viral basic research and drives our pursuit of breakthrough antiviral therapies
Standing at the forefront of antiviral therapy innovation, Ebovir takes on this challenge with its expertise in natural product-derived compounds developed using advanced research tools. Leveraging its deep understanding of virology, the company dedicatedly works on advanced virus engineering, manipulating viral structures and functions to further push the boundaries of antiviral therapy development.
A recent collaboration with a prominent biopharma company based in Boston highlights the pivotal role Ebovir plays in advancing vaccine development initiatives.
Imparting its expertise in virus engineering, the company meticulously validated and verified the efficiency of the client’s vaccine candidates. Generating and analyzing crucial data provided the client with robust insights that helped them file their regulatory submissions appropriately, resulting in FDA’s INDA approval.
Ebovir plans to focus on its commitment to advancing therapeutic solutions. It has subsequently started developing a revolutionary ‘Nano-Lipidfy’ drug delivery system built on nanotechnology to offer greater precision and efficacy in delivering therapeutic agents. This cutting-edge technology, currently in the process of patent filing, represents a significant stride in the field of antiviral therapies in Canada.
On a mission to make meaningful contributions to the field of antiviral therapy development, Ebovir is that perfect partner helping companies bring life-changing drugs to the market. It embodies technological prowess, proficiency in research methodologies, and an undying commitment to maintaining global health security.
